AN OPEN-LABEL EXTENSION TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF DNL310 IN PATIENTS WITH MUCOPOLYSACCHARIDOSIS TYPE II (MPS II) FROM STUDY DNLI-E-0002 OR STUDY DNLI-E-0007

Registry ID

DNLI-E-0008

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

DENALI THERAPEUTICS INC.

Start date

2025-04-04

Last update

2023-10-30

Conditions

• MUCOPOLYSACCHARIDOSIS TYPE II (MPS II)

Related clinical trials

• EFFECT OF ADALIMUMAB ON MUSCULOSKELETAL DISEASE IN MUCOPOLYSACCHARIDOSIS TYPES I, II, IVA AND VI
• A PHASE 2/3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF DNL310 VS IDURSULFASE IN PEDIATRIC PARTICIPANTS WITH NEURONOPATHIC OR NON-NEURONOPATHIC MUCOPOLYSACCHARIDOSIS TYPE II

View on source registry